Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.